World News: 13:00 GMT Tuesday 3rd December 2019. [Celmatix Inc. via Businesswire via SPi World News]
Celmatix Inc., the leading precision health company advancing the fields of reproductive medicine and fertility at the intersection of big data and genomics, today announced a strategic alliance with Evotec, a global leader in drug discovery and development. Today’s news follows an October announcement that the two category leaders would collaborate to develop pre-clinical programs for highly prevalent yet underserved conditions affecting women's reproductive health including endometriosis, polycystic ovary syndrome (PCOS), and infertility. The new alliance will provide support for expansion of Celmatix’s broader, innovative therapeutics initiatives.
“Celmatix was founded on the idea that big data and genomics could be harnessed to provide women reproductive health information earlier in life, helping to drive better decision-making,” explained Dr. Piraye Yurttas Beim, founder and CEO, Celmatix. “These insights, however, are only as powerful as the number of choices a woman has about what to do next, and so the logical next step for us was to also help expand the toolbox in the hands of physicians to help women achieve better health outcomes, more efficiently. This kind of precision health has been revolutionary for categories like oncology, and we are excited about the impact that our alliance with Evotec will have on the field of women’s reproductive health.”
The women’s health therapeutics market is poised for transformation and meaningful growth. More than half a billion women worldwide are impacted by reproductive conditions such as endometriosis and PCOS, but there has been little to no progress in how these and many other related conditions are diagnosed, then treated. Women are having children later in life, leaving a huge unmet need for managing ovarian aging and connecting the dots for women on how certain conditions impact their fertility potential.
Evotec CEO Werner Lanthaler commented, “Over the last 10 years, Celmatix has built the largest, proprietary multi-omic datasets and multidisciplinary expertise in women’s reproductive health. Coupled with our experience developing drugs for hundreds of novel biological targets with top pharmaceutical companies worldwide, we have seen indisputable evidence that data-driven target selection bolsters long-term success for new drug programs. Celmatix is changing the paradigm for women’s health, and we are thrilled to be a part of that remarkable endeavor.”
Evotec is joined in the financing by new investor, the Life Sciences Innovation Fund and existing investors, including Topspin Fund.
Life Sciences Innovation Fund portfolio manager David Sable, MD commented, “The data platform created by Celmatix is unmatched in women’s health. It enables a much more precise understanding of diseases and the patients affected by them, provides a molecular vocabulary that can be used to identify more extensive pathways and targets for intervention, and will create a pipeline of therapeutics, diagnostics and modulators of the immune system, similar to the pace of innovation in areas like oncology.”
No financial terms of this collaboration were disclosed.
Celmatix is a data-driven, research-stage precision health company leveraging insights from its proprietary multi-omic discovery platform, Reproductive Atlas, to develop transformational therapeutics in previously under-studied areas of women’s health. With a lead program in ovarian senescence and additional programs in non-hormonal contraceptives and speciality indications such as endometriosis and polycystic ovary syndrome (PCOS), Celmatix is developing the next generation of interventions in its field, and supporting its partners in bringing innovation to a high-value market with large unmet need. For more information visit .
ABOUT EVOTEC SE
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,900 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go toand follow us on Twitter @Evotec.
Business Wire: 13:00 GMT Tuesday 3rd December 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.